Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 36

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 36
---
                                                                                           
 would be subject to applicable regulatory approval requirements of the foreign countries     
 in which we market our products, which are costly and may prevent or delay us from marketing 
 our products in those countries;                                                             |

| ● | Defending                                                                                 
 against claims relating to improper handling, storage or disposal of hazardous chemicals, 
 radioactive or biological materials could be time consuming and expensive;                |

| ● | Geopolitical                                                                                   
 conditions, including direct or indirect acts of war or terrorism could have an adverse effect 
 on our operations and financial results;                                                       |

| ● | If                                                                                             
 product liability lawsuits are successfully brought against us, then we will incur substantial 
 liabilities and may be required to limit commercialization of Arakoda, Celgosivir or other     
 product candidates;                                                                            |

| ● | Our                                                                                          
 intellectual property rights may not preclude competitors from developing competing products 
 and our business may suffer;                                                                 |

| ● | If                                                                                          
 the manufacture, use or sale of our products infringe on the intellectual property rights   
 of others, we could face costly litigation, which could cause us to pay substantial damages 
 or licensing fees and limit our ability to sell some or all of our products;                |

| ● | We                                                                                
 may not be able to protect our intellectual property rights throughout the world; |

| ● | Patent                                                                                    
 terms may be inadequate to protect our competitive position on our product candidates for 
 an adequate amount of time;                                                               |

| ● | The                                                                                         
 earliest Paragraph IV certification date for Arakoda has passed. Generic companies may file 
 an ANDA at any time, and successful challenge of our malaria use patents would negatively   
 impact our business;                                                                        |

| ● | We                                                                                            
 may not be able to maintain the listing of our common stock on Nasdaq, which could adversely  
 affect our liquidity and the trading volume and market price of our common stock and decrease 
 or eliminate your investment;                                                                 |

| ● | Any                                                                                            
 failure to maintain effective internal controls over financial reporting could have an adverse 
 impact on us; and                                                                              |

| ● | We                                                                                             
 are an “emerging growth company” and a “smaller reporting company”                             
 under the JOBS Act, and we cannot be certain if the reduced disclosure requirements applicable 
 to emerging growth companies and smaller reporting companies will make our common stock less   
 attractive to investors.                                                                       |

Information Regarding our Capitalization As of March 27, 2025 we had 1,472,891 shares of common stock issued and outstanding. Additional information